Hyperhomocysteinemia and Deep-Vein Thrombosis A Case-Control Study

Summary

In a case-control study, fasting total homocysteinemia was determined in 208 consecutive outpatients who underwent phlebography because of the first episode of clinically suspected deep-vein thrombosis (DVT) of lower limbs. Contrast venography confirmed the clinical suspicion in 60 patients (28.8%). Hyperhomocysteinemia was detected in 15 of the 60 patients with DVT (25.0%), and in 17 of the 148 subjects without thrombosis (11.5%; p = 0.025). The OR for having an acute DVT in patients with hyperhomocysteinemia was 2.6 (95% Cl: 1.1-5.9). It is concluded that high plasma homocysteine levels are significantly associated with DVT in symptomatic patients. Further studies are needed to clarify the clinical implications of this association.

• References

• 1 Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-359
• 2 Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: The metabolic basis of inherited disease Scriver C, Beaudet AL, Sly WS, Valle D. (eds). New York, NY: McGraw-Hill: 1989: 693-734
• 3 Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715
• 4 Selhub J, Jacques PF, Bostom AG, D’Agostino RB, Wilson PWF, Belanger AJ, O’Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association, between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-291
• 5 Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881
• 6 Brattström L, Tengbom L, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-57
• 7 Beaumont V, Malinow MR, Sexton G, Wilson D, Lemort N, Upson B, Beaumont JL. Hyperhomocysteinemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives. Atherosclerosis 1992; 94: 147-152
• 8 Bienvenu T, Ankri A, Chadefaux B, Kamoun P. Plasma homocysteine assay in the exploration of thrombosis in young subjects. Press Med 1991; 20: 985-988
• 9 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscl Thromb 1994; 14: 1080-1083
• 10 Fermo I, Viganò D’Angelo S, Paroni R, Mazzola G, Calori G, D’Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753
• 11 den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Wijermans PW, Bos GM. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?. Lancet 1995; 345: 882-885
• 12 den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, Vanden-broucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762
• 13 Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A. Ischemic stroke in young patients with activated protein C resistance: a report of three cases belonging to three different kindreds. Stroke 1995; 26: 885-890
• 14 Girolami A, Simioni P, Girolami B, Marchiori A, Millar DS, Bignell P, Kakkar VV, Cooper DN. A novel dysfunctional protein C (Protein C Padua 2) associated with a thrombotic tendency: substitution of Cys for Arg-1 results in a strongly reduced affinity for binding of Ca⁺⁺ . Br J Haematol 1993; 85: 521-527
• 15 Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Scarano L, Villalta S, Girolami B, Benedetti L, Girolami A. Deep venous thrombosis and lupus anticoagulant: a case-control study. Thromb Haemost 1996; 76: 187-189
• 16 Ubbink JB, Vermaakl WJH, Bissburt S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromat 1991; 565: 441-446
• 17 Lensing AWA, Büller HR, Prandoni P, Batchelor D, Molenaar AHM, Cogo A, Vigo M, Huisman PM, ten Cate JW. Contrast venography, the gold standard for the diagnosis of deep-vein thrombosis: improvement in observer agreement. Thromb Haemost 1992; 67: 8-12
• 18 Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-121
• 19 de Groot PG, Willems C, Boers GH, Gonsalves MD, Van Aken WG, Van Mourik JA. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983; 13: 405-410
• 20 Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376
• 21 Rodgers GM, Kane WH, Pitas RE. Formation of factor Va by atherosclerotic rabbit aorta mediates factor Xa-catalyzed prothrombin activation. J Clin Invest 1988; 81: 1911-1919
• 22 Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901
• 23 den Heijer M, Bos GMJ, Gerrits WBJ, Blom HJ. Will a decrease of blood homocysteine by vitamin supplementation reduce the risk for vascular disease?. Fibrinolysis 1994; 8 (Suppl. 02) 91-92
• 24 Stampfer MJ, Willett WC. Homocysteine and marginal vitamin deficiency: the importance of adequate vitamin intake. JAMA 1993; 270: 2726-2727
• 25 Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk?. N Engl J Med 1995; 332: 328-329